Page 37 of 43

Re: TIL Immunotherapy at NCI

Posted: Thu Dec 14, 2017 2:21 pm
by DAS43
:D Very good news today! The tumor in my lungs has remained the same size but is fading. The Dr thinks it may now be scar tissue left by the dead cancer cell. I will come back in 3 months for test. I am so glad that the Lord brought me here for treatment. Thank you to all of you that have kept me in prayer. I ask that you continue to pray for me and all cancer patients hoping for a miracle

Re: TIL Immunotherapy at NCI

Posted: Thu Dec 14, 2017 3:05 pm
by Robino1
Congratulations. May you continue to get good results! :D

Re: TIL Immunotherapy at NCI

Posted: Thu Dec 14, 2017 8:46 pm
by mariane
Congratulations!!! I am so happy for you!!!

Re: TIL Immunotherapy at NCI

Posted: Fri Dec 15, 2017 6:43 am
by DH2Sleen
DAS43 wrote::D Very good news today! The tumor in my lungs has remained the same size but is fading. The Dr thinks it may now be scar tissue left by the dead cancer cell. I will come back in 3 months for test. I am so glad that the Lord brought me here for treatment. Thank you to all of you that have kept me in prayer. I ask that you continue to pray for me and all cancer patients hoping for a miracle

WOOHOO!!! That is the greatest news. It does take a long time for the fading tumors to go away completely, but they should keep fading. We can't see any sign of the ones we were tracking in Sleen any more; it is now 2 1/2 years since she got her cells.

Re: TIL Immunotherapy at NCI

Posted: Fri Dec 15, 2017 8:40 am
by jdepp
Great news! Happy holidays to you!

Re: TIL Immunotherapy at NCI

Posted: Sat Dec 16, 2017 2:21 pm
by NHMike
For most patients, adoptive cell transfer starts with an operation at the National Cancer Institute. By removing one of your tumors, we are able to find and grow the immune cells that live there, known as tumor-infiltrating lymphocytes or TIL. We will grow and study TIL from your tumor in our labs.
...
With your permission, our referral team may request samples of your tumor to test for certain proteins of interest. For cancers expressing those proteins, patients with certain blood typing (HLA) can be treated without the need for an operation. We perform a large blood collection (called an apheresis) and genetically engineer your white blood cells to recognize those targets.


https://ccr.cancer.gov/sb-faqs

I had thought that NCI was only dealing with folks with KRAS G12D with the HLA-C*0802 or HLA-A*1101 Alleles and maybe G12V in the future. But the text above on their site implies that they will take the cases of folks outside of this relatively small group of people as well. I suspect that they are trying to find other combinations where other Alleles express tumor cells of other kinds gene mutations. If my interpretation is correct, then it should be interesting that they are looking for cures for other mutations and finding them could provide hope for many more people. I do not know if they will find other combinations but I would expect that they would.

If I'm incorrect, please let me know. If there are those in the trial that don't have KRAS G12D or don't have HLA-C*0802 and HLA-A*1101, then that would be evidence that they are working on other mutations which would be exciting.

Re: TIL Immunotherapy at NCI

Posted: Sat Dec 16, 2017 2:32 pm
by DAS43
NHMike
The great thing about this trial is it doesn't matter what your cancer mutations are. What they do is remove a cancer cell find what tumor infiltrating lymphocytes live in that tumor and they design cells that will attack that tumor type. So genetic makeup of the tumor isn't really important because they're going to engineer the cells they give back to you from the tumor that they take. It is truly individualized medicine

Re: TIL Immunotherapy at NCI

Posted: Sat Dec 16, 2017 3:07 pm
by NHMike
DAS43 wrote:NHMike
The great thing about this trial is it doesn't matter what your cancer mutations are. What they do is remove a cancer cell find what tumor infiltrating lymphocytes live in that tumor and they design cells that will attack that tumor type. So genetic makeup of the tumor isn't really important because they're going to engineer the cells they give back to you from the tumor that they take. It is truly individualized medicine


I'm going to have to read more about tumor infiltrating lymphocytes to see how this approach works. The main problem with KRAS, HRAS and NRAS mutations is that the mutation is inside the cell and the immune system can only target cells with structures on the cell surface. In folks with KRAS G12D and HLA-C*0802 and HLA-A*1101, the alleles bring the mutated genes to the cell surface so that the immune system can kill only those cells. So my assumption is that NCI wants to take tumor cells and see if there's an expression of gene mutations on the cell surface that can be targeted by the immune system. Would there always be a presentation of the gene mutation to the cell surface? I'd suspect not given the number of HLAs per person and the very large number of possible HLAs. But I'd love to be wrong.

Update: I did some reading of TILs and the TILs rupture the walls of tumor cells so it appears that the TILs are cells themselves. But that's my reading as someone without a biology background. I'll look around for papers on this stuff and ask my son to look them over.

Re: TIL Immunotherapy at NCI

Posted: Sun Dec 17, 2017 5:22 pm
by rachel2017
Hey, Mike, Thanks for your explanation. Now I have better understanding about Dr Jimmy Yang’s trial. My question is my mom have KRAS mutation: Gly12Asp. What kind of mutation is it? Is this differencing from G12D? Thanks in advanced!
Rachel

Re: TIL Immunotherapy at NCI

Posted: Sun Dec 17, 2017 5:26 pm
by rachel2017
NHMike wrote:For most patients, adoptive cell transfer starts with an operation at the National Cancer Institute. By removing one of your tumors, we are able to find and grow the immune cells that live there, known as tumor-infiltrating lymphocytes or TIL. We will grow and study TIL from your tumor in our labs.
...
With your permission, our referral team may request samples of your tumor to test for certain proteins of interest. For cancers expressing those proteins, patients with certain blood typing (HLA) can be treated without the need for an operation. We perform a large blood collection (called an apheresis) and genetically engineer your white blood cells to recognize those targets.


https://ccr.cancer.gov/sb-faqs

I had thought that NCI was only dealing with folks with KRAS G12D with the HLA-C*0802 or HLA-A*1101 Alleles and maybe G12V in the future. But the text above on their site implies that they will take the cases of folks outside of this relatively small group of people as well. I suspect that they are trying to find other combinations where other Alleles express tumor cells of other kinds gene mutations. If my interpretation is correct, then it should be interesting that they are looking for cures for other mutations and finding them could provide hope for many more people. I do not know if they will find other combinations but I would expect that they would.

If I'm incorrect, please let me know. If there are those in the trial that don't have KRAS G12D or don't have HLA-C*0802 and HLA-A*1101, then that would be evidence that they are working on other mutations which would be exciting.


Hey, Mike, Thanks for your explanation. Now I have better understanding about Dr Jimmy Yang’s trial. My question is my mom have KRAS mutation: Gly12Asp. What kind of mutation is it? Is this differencing from G12D? Thanks in advanced!
Rachel

Re: TIL Immunotherapy at NCI

Posted: Sun Dec 17, 2017 5:36 pm
by Lee
DAS43 wrote::D Very good news today! The tumor in my lungs has remained the same size but is fading. The Dr thinks it may now be scar tissue left by the dead cancer cell. I will come back in 3 months for test. I am so glad that the Lord brought me here for treatment. Thank you to all of you that have kept me in prayer. I ask that you continue to pray for me and all cancer patients hoping for a miracle


That is so totally AWESOME. What a wonderful holiday gift.

To your continued success. . .

Lee

Re: Rejected

Posted: Sun Dec 17, 2017 6:13 pm
by veckon
fighter168 wrote:I called again today. The nurse said that there is no resection site on the liver, it is too dangerous to remove a sample within the liver.


Where are you getting treatment? Might be worth a second opinion from a liver surgeon at MD Anderson or Memorial Sloan Kettering.

Re: TIL Immunotherapy at NCI

Posted: Sun Dec 17, 2017 7:13 pm
by NHMike
rachel2017 wrote:
NHMike wrote:For most patients, adoptive cell transfer starts with an operation at the National Cancer Institute. By removing one of your tumors, we are able to find and grow the immune cells that live there, known as tumor-infiltrating lymphocytes or TIL. We will grow and study TIL from your tumor in our labs.
...
With your permission, our referral team may request samples of your tumor to test for certain proteins of interest. For cancers expressing those proteins, patients with certain blood typing (HLA) can be treated without the need for an operation. We perform a large blood collection (called an apheresis) and genetically engineer your white blood cells to recognize those targets.


https://ccr.cancer.gov/sb-faqs

I had thought that NCI was only dealing with folks with KRAS G12D with the HLA-C*0802 or HLA-A*1101 Alleles and maybe G12V in the future. But the text above on their site implies that they will take the cases of folks outside of this relatively small group of people as well. I suspect that they are trying to find other combinations where other Alleles express tumor cells of other kinds gene mutations. If my interpretation is correct, then it should be interesting that they are looking for cures for other mutations and finding them could provide hope for many more people. I do not know if they will find other combinations but I would expect that they would.

If I'm incorrect, please let me know. If there are those in the trial that don't have KRAS G12D or don't have HLA-C*0802 and HLA-A*1101, then that would be evidence that they are working on other mutations which would be exciting.


Hey, Mike, Thanks for your explanation. Now I have better understanding about Dr Jimmy Yang’s trial. My question is my mom have KRAS mutation: Gly12Asp. What kind of mutation is it? Is this differencing from G12D? Thanks in advanced!
Rachel


The G12D mutation results in an amino acid substitution at position 12 in KRAS, from a glycine (G) to an aspartic acid (D).

https://www.mycancergenome.org/content/ ... r/kras/34/

So yes, G12D.

From MGH's page: https://targetedcancercare.massgeneral. ... D-(c-35G-A).aspx

Image

KRAS is a gene that provides the code for making a protein, KRAS, which is involved primarily in controlling cell division. This protein is part of the MAP kinase signaling cascade (RAS/RAF/MEK/ERK) that relays chemical signals from outside the cell to the cell's nucleus and is primarily involved in controlling cell division. KRAS is an enzyme (a GTPase) that converts a molecule called GTP into GDP. When KRAS is attached (bound) to GDP, it's in its "off" position and can't send signals to the nucleus. But when a GTP molecule arrives and binds to KRAS, KRAS is activated and sends its signal, and then it converts the GTP into GDP and returns to the "off" position.

When mutated, KRAS can act as an oncogene, causing normal cells to become cancerous. The mutations can shift the KRAS protein into the "on" position all the time. KRAS mutations are common in pancreatic, lung and colorectal cancers. These KRAS mutations are said to be somatic, because instead of coming from a parent and being present in every cell (hereditary), they are acquired during the course of a person's life and are found only in cells that become cancerous.

Tumor mutation profiling performed clinically at the MGH Cancer Center has identified KRAS mutations across a broad-spectrum of cancer types. The highest incidence of KRAS mutations have been found in pancreatic cancer (70%), colon cancer (30%), lung cancer (25%), cholangiocarcinoma (15-20%), acute myeloid leukemia (15-20%) and endometrial cancer (15-20%). Across the other major tumor types, KRAS mutations have been found in less than 10% of cases that have been tested.

Re: TIL Immunotherapy at NCI

Posted: Sun Dec 17, 2017 11:07 pm
by rachel2017
The G12D mutation results in an amino acid substitution at position 12 in KRAS, from a glycine (G) to an aspartic acid (D).

https://www.mycancergenome.org/content/ ... r/kras/34/

So yes, G12D.

Thanks a lot! I called NCI and a lady gave me this trial contact information. I was a little bit confused why she didn't give me the information of TIL trial. I thought the TIL trial seems like more established.

Re: TIL Immunotherapy at NCI

Posted: Mon Dec 18, 2017 10:38 am
by NHMike
rachel2017 wrote:The G12D mutation results in an amino acid substitution at position 12 in KRAS, from a glycine (G) to an aspartic acid (D).

https://www.mycancergenome.org/content/ ... r/kras/34/

So yes, G12D.

Thanks a lot! I called NCI and a lady gave me this trial contact information. I was a little bit confused why she didn't give me the information of TIL trial. I thought the TIL trial seems like more established.


Which trial information did you get? Do you have the trial number?